Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure

被引:30
作者
Yonekawa, C
Nakae, H
Tajimi, K
Asanuma, T
机构
[1] Akita Univ, Sch Med, Dept Integrated Med, Div Emergency & Crit Care Med, Akita 0108543, Japan
[2] Akita Univ, Sch Med, Sch Hlth Sci, Akita 010, Japan
关键词
postoperative liver failure; citrate toxicity; interieukin-6; interleukin-18; plasma exchange; continuous hemodialiltration;
D O I
10.1111/j.1525-1594.2005.29054.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Nine patients with postoperative liver failure were treated with plasma exchange (PE) or PE and continuous hemodiafiltration (CHDF), and various biochemical parameters were determined before and after treatment. Although citrate levels increased significantly after treatment compared with pretreatment levels in both the PE group and the PE + CHDF group (P < 0.0001 and P < 0.0001, respectively), the percentage of the increase in citrate levels was significantly higher in the PE group than in the PE + CHDF group (P=0.0051). Total bilirubin (T-Bil) levels were significantly lower after treatment in both the PE and PE + CHDF groups (P<0.0001 and P=0.0001, respectively). There were no significant differences in T-Bil levels between the two groups (P = 0.5181). There were no significant differences in interleukin (IL)-6 levels before and after treatment in both the PE and PE + CHDF groups (P=0.1281 and P=0.2273, respectively). IL-18 levels were significantly lower after treatment in both the PE and PE+CHDF groups (P<0.0001 and P=0.0002, respectively), but there were no significant differences in the removal rate of IL-18 in both the PE and PE + CHDF groups (P=0.8749). These results indicate that combining PE and CHDF in a series-parallel circuit is an effective modality for suppressing the elevation of blood citrate levels. This finding may have important implications for the development of an effective treatment for patients with postoperative liver failure.
引用
收藏
页码:324 / 328
页数:5
相关论文
共 10 条
[1]  
Hirasawa H, 1997, Ther Apher, V1, P228, DOI 10.1111/j.1744-9987.1997.tb00143.x
[2]   Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure [J].
Iwai, H ;
Nagaki, M ;
Naito, T ;
Ishiki, Y ;
Murakami, N ;
Sugihara, J ;
Muto, Y ;
Moriwaki, H .
CRITICAL CARE MEDICINE, 1998, 26 (05) :873-876
[3]  
KERKHOVE MP, 2003, LIVER INT, V23, pS44
[4]   CITRATE INTOXICATION - A CLINICAL AND EXPERIMENTAL STUDY [J].
LUDBROOK, J ;
WYNN, V .
BRITISH MEDICAL JOURNAL, 1958, 2 (AUG30) :522-528
[5]  
Morita Tomoyuki, 2002, J Hepatobiliary Pancreat Surg, V9, P352, DOI 10.1007/s005340200039
[6]   The series-parallel circuit in the treatment of fulminant hepatitis [J].
Nakae, H ;
Yonekawa, C ;
Moon, S ;
Tajimi, K .
THERAPEUTIC APHERESIS AND DIALYSIS, 2004, 8 (02) :153-159
[7]   Involvement of IL-18 and soluble Fas in patients with postoperative hepatic failure [J].
Nakae, H ;
Zheng, YJ ;
Wada, H ;
Tajimi, K ;
Endo, S .
EUROPEAN SURGICAL RESEARCH, 2003, 35 (02) :61-66
[8]   Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure [J].
Sadahiro, T ;
Hirasawa, H ;
Oda, S ;
Shiga, H ;
Nakanishi, K ;
Kitamura, N ;
Hirano, T .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1386-1392
[9]   The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers [J].
Stange, J ;
Hassanein, TI ;
Mehta, R ;
Mitzner, SR ;
Bartlett, RH .
ARTIFICIAL ORGANS, 2002, 26 (02) :103-110
[10]   COMPLICATIONS OF PLASMA-EXCHANGE [J].
SUTTON, DMC ;
NAIR, RC ;
ROCK, G .
TRANSFUSION, 1989, 29 (02) :124-127